Progressive telomere shortening is thought to be important in hematologic neoplasia, TRF shortening has been observed [17][18][19] the regulation of cellular senescence and that the upregulation and in some instances an enhancement of telomerase acti- compared the relative amounts of telomerase activity between (4.53 ± ± ± 0.72 kb vs 6.13 ± ± ± 1.68 kb; P = 0.0005). All samples chronic and blastic phase of CML.
obtained from peripheral blood because of 'dry tap marrow'. All peripheral blood and bone marrow samples were acquired after informed consent was obtained from the patients. Mononuclear cells were obtained by the Ficoll-Hypaque gradient Introduction method, resulting in blast enriched fractions consisting of у80% blast cells in the blastic phase. Telomeres are specialized structures at the ends of eukaryotic chromosomes that help stabilize the ends and appear to protect from illegitimate recombination.
1, 2 Telomere repeats in Fluorescent-labeled (telomeric repeat amplification somatic cells in vitro and in vivo progressively shorten with protocol) TRAP assay each cell division. [3] [4] [5] [6] Telomerase is a ribonucleoprotein enzyme that synthesizes TTAGGG telomeric DNA onto Telomerase activity was assessed according to the method of human chromosomal ends. 7, 8 It has been proposed that the Kim et al 21, 22 with minor modifications. 23, 24 We prepared lysshortening of telomeres may act as a mitotic clock of cell ates from DMSO-free peripheral blood or bone marrow division leading to chromosome instability, additional genetic mononuclear cells stored at −80°C. Briefly, 50 l TRAP reacchanges, reactivation of telomerase (immortalization), telotions, including CHAPS cells extract (5 g), 0.1 g of fluormeric length stabilization and ultimately cancer developescent-labeled TS forward primer (5′-AATCCGTCGAGCAment. [9] [10] [11] GAGTT-3′), 1 g of T4 gene 32 protein, and 2 units of Taq Reduction of telomeric repeats is often seen in various DNA polymerase, were placed over lyophilized fluorescenthuman tumors. [12] [13] [14] Moreover, it has been demonstrated that labeled CX reverse primer (5′-CCCTTACCCTTACCCthe expression of telomerase and ensuing stabilization of tel-TTACCCTAA-3′) using a wax barrier. The microtube was incuomeres appears to be concomitant with the attainment of bated for 20 min at room temperature to allow for telomeraseimmortality in cancer cells. 15, 16 Terminal restriction fragments mediated extension of the TS primer. The mixture then was (TRF), an indication of telomere length, progressively shortheated at 90°C for 90 s, and amplified using polymerase chain ened and may contribute to cell senescence and the proliferatreaction (27 rounds at 94°C for 30 s, 50°C for 30 s, and 72°C ive crisis of virus-infected transformed cells. 16 In human for 1.5 min). The polymerase chain reaction products (1 l) were subjected to 8% denaturing electrophoresis in an automated laser fluorescence (ALF) DNA sequencer II (Pharmacia For standardization of telomerase activity, we used 10 attg/assay of an internal telomerase assay standard (ITAS) which did not interfere with TRAP assay. 23, 25 Amplification of the internal standard generated a 150 bp product which could be reamplified using the same TS and CX primers used to amplify telomerase ladder in the standard TRAP assay. 25 The telomerase activity signals in each sample using 2 × 10 3 cells equivalent per assay were normalized to the signal from 10 attg per assay of ITAS, then expressed as a relative value of ITAS. We also assessed telomerase activity in peripheral mononuclear cells obtained from normal healthy volunteers (n = 55; aged 4 to 90 years old).
Telomeric repeat analysis TRF was assessed using the (TTAGGG) 4 probe and Southern blot analysis, as described previously. 17 Autoradiographs were captured in an Image Master (Pharmacia Biotech) and the peak point was determined and expressed in kilobases (kb). We calculated age-matched expected TRF by the formulation: T (kb) = 11.85 − 0.042 × A (age, years).
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Figure 1
Telomerase activity in CML patients. P Ͻ 0.05 were considered significant. Statistical tests were performed using the Statview software package for the Macintosh personal computer.
Results
Telomerase activity in normal blood cells
We first assessed telomerase activity in peripheral blood cells obtained from 55 healthy volunteers (4-90 years of age) and bone marrow cells obtained from four healthy volunteers (30-45 years old). The mean relative value of telomerase activity was generally stronger in children than in older individuals (0 at 90 years old to 13.4 at 4 years old). Telomerase activity of normal peripheral blood cells is as follows:
7.2 ± 5.0 relative value in aged Ͻ19 years (n = 6) 2.0 ± 1.9 relative value in aged 20-39 years (n = 16) 0.5 ± 0.7 relative value in aged 40-59 years (n = 16) 0.7 ± 0.8 relative value in aged 60-79 years (n = 10) 0.7 ± 0.6 relative value in aged Ͼ80 years (n = 7)
Figure 2
In a chronic myeloid leukemia patient (UPN 101 in Table   The mean Telomerase activity in CML patients low: above normal and up to 10 relative value; moderate: 10 to 50 relative value; high: Ͼ50 relative value, ie almost equivalent to immortalized leukemia cell lines. We determined telomerase activity in 33 patients with CML in the chronic phase. We arbitrarily separated CML patients All the CML patients in the chronic phase in this study had detectable telomerase activity which ranged from 1.9 to 15.7 into four groups regarding telomerase activity as follows: normal range: Ͻmean + 2 s.d. of that in peripheral blood cells relative value (Figures 1 and 2 ). Seven patients in the chronic phase of CML had telomerase activity within the normal range activity or not (leukocytes, P = 0.40; hemoglobin P = 0.85; platelets, P = 0.47; peripheral blast percentage, P = 0.20; marof age-matched telomerase activity, 23 had low, and three patients had moderate telomerase activity, even in the chronic row blast percentage, P = 0.93). No significant differences in duration of chronic phase (P = 0.78) or duration of blastic phase (Table 1) .
In the blastic phase (n = 21), telomerase activity levels range phase (P = 0.83) were also evident. Additional cytogenetic changes were observed in 11/11 patients with telomerase from 3.4 to 138.8 ( Figures 1 and 2) ; the telomerase activity in the blastic phase was significantly higher than that in the activity у10 relative value and 5/10 patients with Ͻ10 relative value of telomerase activity (P = 0.01 determined by the Fishchronic phase (33.84 ± 37.86 vs 6.08 ± 3.21; P = 0.0159). No CML patient in the blast phase showed telomerase activity er's test). within the normal range (Table 1) ; we identified 11 patients showing low telomerase activity, four patients had moderate (10-50 relative value) and seven had high telomerase activity Discussion (Ͼ50 relative value) ( Table 1) .
We determined telomerase activity in 13 patients in both Many types of tumors, including hematopoietic neoplasias, have reduced telomere lengths as determined by TRF analythe chronic and blast phases. Seven of the 13 patients showed a two-fold increase in telomerase activity in blast phase when sis.
14 The reduction of TRF in cancer cells might be linked to the number of cell divisions, 26 possibly caused by the incomcompared to the chronic phase ( Terminal restriction fragment length in CML patients insufficient to prevent progressive shortening of the TRFs, since reduction of TRFs in the peripheral blood cells correlates The TRFs of bone marrow mononuclear cells obtained from 33 patients with CML ranged from 3.2 kb to 9.9 kb with increased age. 26 CML patients in the chronic phase had significantly shorter TRFs and all had detectable telomerase (6.13 ± 1.68 kb) at the time of diagnosis (ie chronic phase). We then calculated the expected TRF based on each patient's activity in the chronic phase; 79% of them had slightly elevated telomerase activity compared to the normal peripheral age. 17 The TRF in the chronic phase of CML patients was significantly shortened compared to that of the age-matched blood cells. Since most individuals aged over 40 years had very low or undetectable telomerase activity in the peripheral expected TRF of these patients (6.13 ± 1.68 kb vs 9.98 ± 0.62 kb; P = 0.0001). In the blastic phase, the TRFs blood, slight elevated telomerase activity in CML in the chronic phase may reflect telomerase activity in the CML ranged from 3.2 kb to 5.5 kb (4.53 ± 0.72 kb). The TRF in the blastic phase was significantly shortened compared to the agecells. During the process of establishment of leukemia cell lines, matched expected TRF (P = 0.0001) or to that in the chronic phase (P = 0.0005).
enhancement of telomerase activity is associated with reduction of telomere lengths and an appearance of telomeric association, ie dicentric chromosomes or acentric fragments.
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This suggests that critical reduction of telomere length in neo-
Comparison of hematologic findings to telomerase activity and TRF in the blastic phase plastic cells, including leukemia cells, may be linked to upregulation of telomerase activity and additional chromosome changes, similar to those we and others previously reported Based on the difference of telomerase activity in the blast phase, we tentatively separated CML-blast phase patients in the cell culture model system. 15, 16 Although we determined only one CML patient (UPN 110) in the blast phase whose (n = 21) into two groups, ie those with relative value Ͻ10 (low telomerase activity in Table 1 ) and those with that Ͼ10 leukemia cells had a ring chromosome, additional cytogenetic changes were frequently observed in CML-blast phase with an (moderate and high telomerase activity in Table 1 ). No significant differences in hematologic findings at the blastic enhancement of telomerase activity and reduction of telomere length. Double minutes or ring chromosome are thought to phase were evident whether the cells had high telomerase be unstable during the process of cell division, thus such aberrations are only rarely detectable at the clinical level. Telo- ined for other cytogenetic changes. Our analyses demon- strated a correlation between levels of telomerase activity and In summary, while we observed statistically significant changes in telomerase activity and telomere length when additional cytogenetic changes. This suggests that telomerase reactivation is associated with the presence of additional cytocomparing CML in chronic vs blastic phase, caution is urged since this was a relatively small study. In addition, at the genetic changes and this may be one pathway of disease progression in CML. However, no evidence was obtained that present time, we cannot distinguish between elevated levels of telomerase activity in a small subset of important cells (such patients with CML-blast phase showing high telomerase activity had shorter TRFs when compared to those CML-blast as progenitor cells) and the telomerase activity from the rest of the cell population. However, these initial results suggest phase patients with low or moderate telomerase activity. The high replicative capability of CML cells in the chronic phase that telomerase activity and telomere length measurements during CML disease progression may in the future have clinimight induce progressive telomere shortening. One explanation might be that active cell division of hematopoietic cells cal utility for better management of patient care. without apparent upregulation of telomerase activity results in telomere erosion. Acknowledgement In the blast phase, reduction of telomere lengths were significant compared to that in chronic phase, and about 50%
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